Key result
Riliprubart enters two actively enrolling Phase 3 trials for chronic inflammatory demyelinating polyradiculoneuropathy.
Why the study?
The study was conducted to describe the study designs of two riliprubart Phase-3 trials for chronic inflammatory demyelinating polyradiculoneuropathy and provide an update on recruitment status.
Describes the study designs and recruitment status of two Phase-3 trials for riliprubart in CIDP.
Riliprubart Phase-3 CIDP trial designs are now public; leaves open efficacy and practice impact until results emerge.
To describe the study designs of two riliprubart Phase-3 trials for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), MOBILIZE (NCT06290128) and VITALIZE (NCT06290141), and provide an update on recruitment status.
No takes yet. Share an insight, caveat, or question.
Sommer et al. (2026) studied this question. Riliprubart is currently being evaluated in two actively enrolling Phase 3 trials, MOBILIZE and VITALIZE, for chronic inflammatory demyelinating polyradiculoneuropathy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: